Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples

被引:5
作者
de la Bletiere, Diane Raingeard [1 ,2 ,3 ]
Blanchet, Odile [2 ,3 ,4 ]
Cornillet-Lefebvre, Pascale [5 ]
Coutolleau, Anne [1 ]
Baranger, Laurence [6 ]
Genevieve, Franck [4 ]
Luquet, Isabelle [5 ]
Hunault-Berger, Mathilde [7 ]
Beucher, Annaelle [4 ]
Schmidt-Tanguy, Aline [2 ,3 ,7 ]
Zandecki, Marc [4 ]
Delneste, Yves [2 ,3 ]
Ifrah, Norbert [2 ,3 ,7 ]
Guardiola, Philippe [1 ,2 ,3 ,7 ]
机构
[1] CHU Angers, Plateforme SNP Transcriptome & Epigen, Angers, France
[2] Univ Angers, Ctr Rech Canc Nantes Angers, INSERM, U892, Angers, France
[3] Univ Angers, UMR S 892, Angers, France
[4] CHU Angers, Hematol Lab, Angers, France
[5] Ctr Hosp Univ, Hematol Lab, Reims, France
[6] CHU Angers, Genet Lab, Angers, France
[7] CHU Angers, Serv Malad Sang, Angers, France
来源
BMC MEDICAL GENOMICS | 2012年 / 5卷
关键词
NORMAL KARYOTYPE; RT-PCR; MUTATIONS; AML; REARRANGEMENTS; IDENTIFICATION; SIGNATURES; PROGNOSIS; DIAGNOSIS; DISTINCT;
D O I
10.1186/1755-8794-5-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Gene expression profiling has shown its ability to identify with high accuracy low cytogenetic risk acute myeloid leukemia such as acute promyelocytic leukemia and leukemias with t(8; 21) or inv(16). The aim of this gene expression profiling study was to evaluate to what extent suboptimal samples with low leukemic blast load (range, 2-59%) and/or poor quality control criteria could also be correctly identified. Methods: Specific signatures were first defined so that all 71 acute promyelocytic leukemia, leukemia with t(8; 21) or inv(16)-AML as well as cytogenetically normal acute myeloid leukemia samples with at least 60% blasts and good quality control criteria were correctly classified (training set). The classifiers were then evaluated for their ability to assign to the expected class 111 samples considered as suboptimal because of a low leukemic blast load (n = 101) and/or poor quality control criteria (n = 10) (test set). Results: With 10-marker classifiers, all training set samples as well as 97 of the 101 test samples with a low blast load, and all 10 samples with poor quality control criteria were correctly classified. Regarding test set samples, the overall error rate of the class prediction was below 4 percent, even though the leukemic blast load was as low as 2%. Sensitivity, specificity, negative and positive predictive values of the class assignments ranged from 91% to 100%. Of note, for acute promyelocytic leukemia and leukemias with t(8; 21) or inv(16), the confidence level of the class assignment was influenced by the leukemic blast load. Conclusion: Gene expression profiling and a supervised method requiring 10-marker classifiers enable the identification of favorable cytogenetic risk acute myeloid leukemia even when samples contain low leukemic blast loads or display poor quality control criterion.
引用
收藏
页数:12
相关论文
共 34 条
[1]   Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Care, RS ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :983-988
[2]   Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance [J].
Alcalay, M ;
Tiacci, E ;
Bergomas, R ;
Bigerna, B ;
Venturini, E ;
Minardi, SP ;
Meani, N ;
Diverio, D ;
Bernard, L ;
Tizzoni, L ;
Volorio, S ;
Luzi, L ;
Colombo, E ;
Lo Coco, F ;
Mecucci, C ;
Falini, B ;
Pelicci, PG .
BLOOD, 2005, 106 (03) :899-902
[3]   Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations:: a concise review [J].
Baldus, Claudia D. ;
Mrozek, Krzysztof ;
Marcucci, Guido ;
Bloomfield, Clara D. .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) :387-400
[4]   Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype [J].
Boissel, N ;
Renneville, A ;
Biggio, V ;
Philippe, N ;
Thomas, X ;
Cayuela, JM ;
Terre, C ;
Tigaud, I ;
Castaigne, S ;
Raffoux, E ;
De Botton, S ;
Fenaux, P ;
Dombret, H ;
Preudhomme, C .
BLOOD, 2005, 106 (10) :3618-3620
[5]   Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype [J].
Breems, Dimitri A. ;
Van Putten, Wim L. J. ;
De Greef, Georgine E. ;
Van Zelderen-Bhola, Shama L. ;
Gerssen-Schoorl, Klasien B. J. ;
Mellink, Clemens H. M. ;
Nieuwint, Aggie ;
Jotterand, Martine ;
Hagemeijer, Anne ;
Beverloo, H. Berna ;
Lowenberg, Bob .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4791-4797
[6]   Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia [J].
Bullinger, L ;
Döhner, K ;
Bair, E ;
Fröhling, S ;
Schlenk, RF ;
Tibshirani, R ;
Döhner, H ;
Pollack, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1605-1616
[7]   Purity for clarity: the need for purification of tumor cells in DNA microarray studies [J].
de Ridder, D ;
van der Linden, C ;
Schonewille, T ;
Dik, WA ;
Reinders, MJT ;
van Dongen, JJM ;
Staal, FJT .
LEUKEMIA, 2005, 19 (04) :618-627
[8]   Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].
Doehner, Hartmut ;
Estey, Elihu H. ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Burnett, Alan K. ;
Dombret, Herve ;
Fenaux, Pierre ;
Grimwade, David ;
Larson, Richard A. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel A. ;
Sierra, Jorge ;
Tallman, Martin S. ;
Loewenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2010, 115 (03) :453-474
[9]  
Falkenauer E, 1998, GENETIC ALGORITHMS G, P81
[10]   Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].
Gabert, J ;
Beillard, E ;
van der Velden, VHJ ;
Bi, W ;
Grimwade, D ;
Pallisgaard, N ;
Barbany, G ;
Cazzaniga, G ;
Cayuela, JM ;
Cavé, H ;
Pane, F ;
Aerts, JLE ;
De Micheli, D ;
Thirion, X ;
Pradel, V ;
González, M ;
Viehmann, S ;
Malec, M ;
Saglio, G ;
van Dongen, JJM .
LEUKEMIA, 2003, 17 (12) :2318-2357